कृपया अन्य खोज का प्रयास करें
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Domenick T. Zero | - | - | Member of C16G2 Clinical Advisory Board |
Ann Griffen | - | - | Member of C16G2 Clinical Advisory Board |
Mark S. Wolff | - | - | Member of C16G2 Clinical Advisory Board |
Todd C. Peterson | 65 | 2019 | Independent Director |
Athena Papas | - | - | Member of C16G2 Clinical Advisory Board |
Joseph M. Patti | 60 | 2019 | Independent Director |
Odysseas D. Kostas | 49 | 2020 | Independent Director |
James Bader | - | - | Member of C16G2 Clinical Advisory Board |
Deborah L. Birx | 67 | 2023 | CEO & Director |
Robin C. Kramer | 58 | 2020 | Independent Chairman of the Board |
Sarah J. Schlesinger | 64 | 2020 | Independent Director |
Jules A. Haimovitz | 73 | 2021 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है